Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells

[1]  M. Renner,et al.  Suicide genes for cancer therapy. , 2007, Molecular aspects of medicine.

[2]  P. Schlag,et al.  Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter–regulated tumor necrosis factor-α expression , 2007, Molecular Cancer Therapeutics.

[3]  Zhenwu Du,et al.  Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors. , 2005, Chinese medical journal.

[4]  A. Morokoff,et al.  Targeted therapy for malignant gliomas , 2004, Journal of Clinical Neuroscience.

[5]  U. Bogdahn,et al.  Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma , 2004, Cancer.

[6]  M. Asaka,et al.  In vitro model of suicide gene therapy for alpha-fetoprotein-producing gastric cancer. , 2003, Anticancer research.

[7]  Michael C. Montalto,et al.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. , 2002, Cancer research.

[8]  Xin-Yuan Liu,et al.  Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene. , 2002, World journal of gastroenterology.

[9]  Qingling Zhang,et al.  Establishment of multidrug-resistance cell line C(6)/adr and reversal of drug-resistance. , 2002, Chinese medical journal.

[10]  Daxi Sun,et al.  Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1* , 2001, The Journal of Biological Chemistry.

[11]  J. Lebkowski,et al.  The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters , 2001, Gene Therapy.

[12]  B. Ogretmen,et al.  Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. , 2000, Biochemistry.

[13]  B. Ogretmen,et al.  Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. , 1999, Biochemistry.

[14]  K. Kohno,et al.  Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene* , 1998, The Journal of Biological Chemistry.

[15]  R. Sundseth,et al.  DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. , 1997, Molecular pharmacology.

[16]  P. Sonneveld,et al.  Clinical relevance of P-glycoprotein expression in haematological malignancies. , 1994, Leukemia research.

[17]  K. Cowan,et al.  Identification of 5' and 3' sequences involved in the regulation of transcription of the human mdr1 gene in vivo. , 1993, The Journal of biological chemistry.

[18]  C. Bloomfield,et al.  Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. , 1992, Cancer research.

[19]  M. Tolomeo,et al.  Selection of a new multidrug resistant cell line from Friend leukemia cells by short and cyclic exposures to high concentrations of daunorubicin. , 1992, Haematologica.

[20]  M. Benchekroun,et al.  Chromosomal modifications of a rat glioblastoma cell line during the acquisition and reversal of doxorubicin resistance. , 1990, Anticancer research.

[21]  K. Cowan,et al.  Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. , 1990, Molecular pharmacology.

[22]  V. Ling,et al.  Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Pastan,et al.  Expression of a human multidrug resistance gene in ovarian carcinomas. , 1989, Cancer research.

[24]  J. Epstein,et al.  P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. , 1989, Blood.

[25]  I. Roninson,et al.  An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene , 1988, Cell.

[26]  I. Pastan,et al.  Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Ling,et al.  P-glycoprotein in human sarcoma: evidence for multidrug resistance. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  V. Ling,et al.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Gaoshen,et al.  Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors , 2005 .

[30]  A. Stavrovskaya.  Cellular mechanisms of multidrug resistance of tumor cells. , 2000, Biochemistry. Biokhimiia.

[31]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  V. Ling,et al.  Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies , 1985, Nature.